CL2015001419A1 - Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor. - Google Patents

Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.

Info

Publication number
CL2015001419A1
CL2015001419A1 CL2015001419A CL2015001419A CL2015001419A1 CL 2015001419 A1 CL2015001419 A1 CL 2015001419A1 CL 2015001419 A CL2015001419 A CL 2015001419A CL 2015001419 A CL2015001419 A CL 2015001419A CL 2015001419 A1 CL2015001419 A1 CL 2015001419A1
Authority
CL
Chile
Prior art keywords
tarp
pyrazol
benzothiazole
pyridin
ethoxy
Prior art date
Application number
CL2015001419A
Other languages
English (en)
Spanish (es)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2015001419A1 publication Critical patent/CL2015001419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015001419A 2012-11-27 2015-05-26 Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor. CL2015001419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27

Publications (1)

Publication Number Publication Date
CL2015001419A1 true CL2015001419A1 (es) 2015-10-02

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001419A CL2015001419A1 (es) 2012-11-27 2015-05-26 Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TW201825484A (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CA2984290C (en) * 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
JP6800885B2 (ja) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
ATE404555T1 (de) * 2004-12-17 2008-08-15 Lilly Co Eli Neue mch-rezeptorantagonisten
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
JP2012505198A (ja) * 2008-10-08 2012-03-01 ファイザー・インク Ｃｎｓ障害を治療する際にａｍｐａ調節剤として使用するためのテトラヒドロフラニルスルホンアミド
HRP20150355T1 (hr) * 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
JP6088425B2 (ja) * 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Also Published As

Publication number Publication date
PL2925754T3 (pl) 2017-07-31
US8765960B2 (en) 2014-07-01
EP2925754B1 (en) 2016-12-28
JP6246227B2 (ja) 2017-12-13
AR093527A1 (es) 2015-06-10
HK1209116A1 (en) 2016-03-24
TN2015000200A1 (en) 2016-10-03
PE20151728A1 (es) 2015-12-02
CA2889243A1 (en) 2014-06-05
TW201434834A (zh) 2014-09-16
EA201590823A1 (ru) 2015-08-31
WO2014085153A8 (en) 2014-07-31
AU2013352594A1 (en) 2015-06-04
MX356478B (es) 2018-05-30
BR112015011200A2 (pt) 2017-07-11
PH12015501154B1 (en) 2018-05-30
JO3225B1 (ar) 2018-03-08
EP2925754A1 (en) 2015-10-07
CA2889243C (en) 2017-06-13
AU2013352594B2 (en) 2016-02-18
SI2925754T1 (sl) 2017-02-28
TWI618705B (zh) 2018-03-21
UA114345C2 (uk) 2017-05-25
MA38126A1 (fr) 2017-03-31
CN104797578B (zh) 2016-11-23
MX2015006697A (es) 2015-08-05
KR101693133B1 (ko) 2017-01-04
SG11201504164VA (en) 2015-07-30
MA38126B1 (fr) 2017-11-30
HRP20170274T1 (hr) 2017-04-07
PT2925754T (pt) 2017-02-27
ZA201503733B (en) 2017-09-27
IL238831A0 (en) 2015-06-30
PH12015501154A1 (en) 2015-08-10
IL238831B (en) 2018-08-30
DK2925754T3 (en) 2017-02-20
JP2016501219A (ja) 2016-01-18
DOP2015000113A (es) 2015-06-15
CY1118657T1 (el) 2017-07-12
US20140148441A1 (en) 2014-05-29
MY177721A (en) 2020-09-23
KR20150070401A (ko) 2015-06-24
EA026686B1 (ru) 2017-05-31
AP2015008489A0 (en) 2015-05-31
CR20150267A (es) 2015-09-16
TW201825484A (zh) 2018-07-16
WO2014085153A1 (en) 2014-06-05
HUE033447T2 (en) 2017-11-28
CN104797578A (zh) 2015-07-22
ES2618260T3 (es) 2017-06-21

Similar Documents

Publication Publication Date Title
CL2015001419A1 (es) Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
JOP20130313B1 (ar) عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
CL2014002756A1 (es) Compuestos derivados de 1,4-benzotiazepina; composición farmacéutica que lo comprende; uso para tratar afecciones relacionadas con función anormal de receptores de rianodina; y método de preparación del compuesto.
DK2976074T3 (da) Antagonister af cannabinoid-receptoren CB1 til anvendelse ved behandling af sygdomme associeret med neuronale dendritiske anormaliteter
CL2012002506A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores de la enzima pde10; composiciones farmacéuticas que comprenden dichos compuestos; y un método para tratar desórdenes neurológicos en un animal de sangre caliente, tal como esquizofrenia.
DK2773633T3 (da) Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf.
GB201415655D0 (en) System, method, and interfaces for work product management
PT3069720T (pt) Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
MX2015007051A (es) Diazol lactamas.
CL2015001516A1 (es) Compuestos derivados de piridopirazinas sustituidas, inhibidores de syk; composicion farmaceutica; metodo para tratar una enfermedad inflamatoria, alergias, enfermedad autoinmune, enfermedad proliferativa celular, entre otras.
EP2753329A4 (en) 1,5-Naphthyridine inhibitor and Melk inhibitor with it
WO2014160956A3 (en) Cartilage-binding fusion proteins
BR112015009738A2 (pt) composto, composição farmacêutica, método para o tratamento de uma condição ou distúrbio em que bloqueadores de canal ttx-s são envolvidos, em um animal, incluindo um humano e processo para preparar uma composição farmacêutica.
BR112017017317A2 (pt) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4- (etoxioxalilamino)-2-hidroximetil-2-metilpentanóico como inibidor de neprilisina
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
WO2012080641A8 (fr) Agonistes des recepteurs s1p et leur utilisation dans le traitement des infections du vih
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
EP2925760A4 (en) C20'-UREA DERIVATIVES OF VINCALAL ALCOHOLS
CL2015000890A1 (es) Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.
EP2835424A4 (en) DNA-CONTROL MIR-140 EXPRESSION AND MEDICINE SCREENING METHOD WITH THIS DNA
FR2958160B1 (fr) Procede de traitement des cheveux mettant en oeuvre trois compositions dont deux emulsions directes particulieres
SI3057580T1 (sl) Farmacevtske dozirne oblike, ki vsebujejo natrijev 1-(6-(morfolin-4-il)pirimidin-4-il)-4-(1H-1,2,3-triazol-1-il)-1H- pirazol-5-olat
FR3045365B1 (fr) Composition comprenant d'alkylcellulose, des huiles hydrocarbonees et siliconees incompatibles et procede la mettant en oeuvre